[go: up one dir, main page]

WO2005046575A3 - Amino acid prodrugs - Google Patents

Amino acid prodrugs Download PDF

Info

Publication number
WO2005046575A3
WO2005046575A3 PCT/US2004/024901 US2004024901W WO2005046575A3 WO 2005046575 A3 WO2005046575 A3 WO 2005046575A3 US 2004024901 W US2004024901 W US 2004024901W WO 2005046575 A3 WO2005046575 A3 WO 2005046575A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
present
acid prodrugs
drug
directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/024901
Other languages
French (fr)
Other versions
WO2005046575A2 (en
Inventor
V Ravi Chandran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signature R&D Holdings LLC
Original Assignee
Signature R&D Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020137015399A priority Critical patent/KR20130081319A/en
Priority to AU2004289174A priority patent/AU2004289174B2/en
Priority to EP04816791A priority patent/EP1660017A4/en
Priority to NZ545570A priority patent/NZ545570A/en
Priority to CA2534342A priority patent/CA2534342C/en
Priority to JP2006522125A priority patent/JP2007510621A/en
Application filed by Signature R&D Holdings LLC filed Critical Signature R&D Holdings LLC
Publication of WO2005046575A2 publication Critical patent/WO2005046575A2/en
Priority to IL173382A priority patent/IL173382A0/en
Anticipated expiration legal-status Critical
Priority to US11/343,557 priority patent/US8173840B2/en
Priority to US11/442,027 priority patent/US7589233B2/en
Publication of WO2005046575A3 publication Critical patent/WO2005046575A3/en
Priority to US12/556,968 priority patent/US8563776B2/en
Priority to US12/557,030 priority patent/US8188311B2/en
Priority to US12/557,080 priority patent/US20100069489A1/en
Priority to US13/449,791 priority patent/US20120289471A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention is directed to a prodrug comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The prodrug has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the prodrugs of the present invention enhance at least two therapeutic qualities, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.
PCT/US2004/024901 2003-07-29 2004-07-29 Amino acid prodrugs Ceased WO2005046575A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
KR1020137015399A KR20130081319A (en) 2003-07-29 2004-07-29 Amino acid prodrugs
AU2004289174A AU2004289174B2 (en) 2003-07-29 2004-07-29 Amino acid prodrugs
EP04816791A EP1660017A4 (en) 2003-07-29 2004-07-29 Amino acid prodrugs
NZ545570A NZ545570A (en) 2003-07-29 2004-07-29 Amino acid prodrugs
CA2534342A CA2534342C (en) 2003-07-29 2004-07-29 Amino acid prodrugs
JP2006522125A JP2007510621A (en) 2003-07-29 2004-07-29 Amino acid prodrug
IL173382A IL173382A0 (en) 2003-07-29 2006-01-26 Amino acid prodrugs
US11/343,557 US8173840B2 (en) 2003-07-29 2006-01-30 Compounds with high therapeutic index
US11/442,027 US7589233B2 (en) 2003-07-29 2006-05-26 L-Threonine derivatives of high therapeutic index
US12/557,080 US20100069489A1 (en) 2003-07-29 2009-09-10 L-threonine derivatives of high therapeutic index
US12/556,968 US8563776B2 (en) 2003-07-29 2009-09-10 L-Threonine derivatives of high therapeutic index
US12/557,030 US8188311B2 (en) 2003-07-29 2009-09-10 L-threonine derivatives of high therapeutic index
US13/449,791 US20120289471A1 (en) 2003-07-29 2012-04-18 Novel compounds with high therapeutic index

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49133103P 2003-07-29 2003-07-29
US60/491,331 2003-07-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/343,557 Continuation-In-Part US8173840B2 (en) 2003-07-29 2006-01-30 Compounds with high therapeutic index

Publications (2)

Publication Number Publication Date
WO2005046575A2 WO2005046575A2 (en) 2005-05-26
WO2005046575A3 true WO2005046575A3 (en) 2007-10-04

Family

ID=34590076

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/024901 Ceased WO2005046575A2 (en) 2003-07-29 2004-07-29 Amino acid prodrugs

Country Status (11)

Country Link
EP (1) EP1660017A4 (en)
JP (2) JP2007510621A (en)
KR (3) KR20120116991A (en)
CN (1) CN101123878A (en)
AU (1) AU2004289174B2 (en)
CA (1) CA2534342C (en)
IL (1) IL173382A0 (en)
NZ (3) NZ601772A (en)
SG (2) SG178721A1 (en)
WO (1) WO2005046575A2 (en)
ZA (1) ZA200600660B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645792B2 (en) 2004-07-12 2010-01-12 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603512A2 (en) 2003-03-17 2005-12-14 Albany Molecular Research, Inc. Novel cyclosporins
KR20120116991A (en) * 2003-07-29 2012-10-23 시그너쳐 알 앤드 디 홀딩스, 엘엘씨 Amino acid prodrugs
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
JP2007517056A (en) 2003-12-29 2007-06-28 セプラコア インコーポレーテッド Pyrrole and pyrazole DAAO inhibitors
CN101921347B (en) * 2004-01-07 2014-07-30 生化学工业株式会社 Hyaluronic acid derivative and drug containing the same
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
EP1812037A4 (en) 2004-10-06 2009-11-11 Amr Technology Inc Novel cyclosporin alkynes and their utility as pharmaceutical agents
WO2006117567A2 (en) * 2005-05-05 2006-11-09 Chroma Therapeutics Ltd Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
WO2007059047A2 (en) * 2005-11-11 2007-05-24 Chandran V Ravi Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements
CN101426372A (en) 2006-01-06 2009-05-06 塞普拉柯公司 Tetralone-based monoamine reuptake inhibitors
RU2430913C2 (en) 2006-01-06 2011-10-10 Сепракор Инк. Cycloalkylamines as monoamine reuptake inhibitors
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
PT2013835E (en) 2006-03-31 2016-01-06 Sunovion Pharmaceuticals Inc Preparation of chiral amides and amines
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
EP2049101A4 (en) * 2006-07-06 2010-09-15 Cytovia Inc 4-ARYL-CHROMENE SUBSTITUTED AS CAPSASE ACTIVATOR AND INDUCER OF APOPTOSIS AND AS AN ANTI-VASCULAR AGENT, AND USE
CN1907954B (en) * 2006-08-16 2011-11-23 重庆医科大学医药研究所 Water-soluble derivative of anesthetic 2,6-diisopropyl phenol and preparation method thereof
WO2008053131A1 (en) 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
KR101581289B1 (en) 2007-05-31 2015-12-31 세프라코 아이엔시. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
WO2008157537A2 (en) * 2007-06-19 2008-12-24 Ironwood Pharmaceuticals, Inc Compositions and methods of use for treating or preventing lipid related disorders
JP5555186B2 (en) 2008-02-29 2014-07-23 クロマ セラピューティクス リミテッド p38 MAP kinase inhibitor
TWI424832B (en) * 2008-12-15 2014-02-01 Proteus Digital Health Inc Body-associated receiver and method
MX2011006075A (en) 2008-12-19 2011-09-27 Pinnacle Pharmaceuticals Inc Phenazopyridine compounds.
CN102596896A (en) * 2009-06-24 2012-07-18 夏尔有限责任公司 Mexiletine amino acid and peptide prodrugs and uses thereof
PH12012500870A1 (en) 2009-11-12 2012-11-26 Univ Michigan Regents Spiro-oxindole mdm2 antagonists
MX2012008922A (en) 2010-02-01 2012-10-05 Proteus Digital Health Inc Data gathering system.
CN101906039B (en) * 2010-06-23 2013-05-08 四川大学华西医院 Hydroxy acid ester compound of substituted phenol, preparation method and application in medicine
MX2010011006A (en) 2010-10-06 2012-04-18 Senosiain S A De C V Lab New salt of a pyrimidin derivative.
PE20140408A1 (en) 2010-11-12 2014-04-10 Univ Michigan SPIRO-OXINDOL DERIVATIVES AS ANTAGONISTS OF MDM2
WO2012085586A1 (en) * 2010-12-23 2012-06-28 Shire, Llc Mexiletine prodrugs
EP2707372B1 (en) 2011-05-11 2016-12-21 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
FR2976944A1 (en) 2011-06-21 2012-12-28 Centre Nat Rech Scient PEPTIDE PRODUCTS
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
EP2773378B1 (en) 2011-10-31 2016-08-10 Larsen, Claus Selch Prodrugs of non-steroid anti-inflammatory agents (nsaids)
AU2013202982C1 (en) 2012-01-06 2017-01-05 Novartis Ag Heterocyclic compounds and methods for their use
RU2683934C2 (en) * 2012-01-18 2019-04-03 Текфилдз Фарма Ко., Лтд. High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
WO2013168024A1 (en) * 2012-05-07 2013-11-14 Mahesh Kandula Prodrugs of anti-platelet agents
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
SG11201407303SA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
SG11201407322QA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of multiple sclerosis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
AU2013264894B2 (en) 2012-05-23 2015-11-19 Cellix Bio Private Limited Compositions and methods for treatment of inflammatory bowel disease
EP2852571A4 (en) 2012-05-23 2015-11-25 Cellix Bio Private Ltd Compositions and methods for the treatment of mucositis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
TWI601725B (en) * 2012-08-27 2017-10-11 加拓科學公司 Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
CN102924398B (en) * 2012-11-22 2015-11-18 安徽贝克生物制药有限公司 For removing the method for the corresponding isomer of efavirenz
CN103880754A (en) * 2012-12-21 2014-06-25 西藏海思科药业集团股份有限公司 Alkaline amino acid ester salt of propofol
JP6498177B2 (en) 2013-03-15 2019-04-10 プロテウス デジタル ヘルス， インコーポレイテッド Identity authentication system and method
CN103263405B (en) * 2013-05-08 2015-04-22 南京医科大学 Medicinal composition for treating diabetes, and its application
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
CN103360240B (en) * 2013-07-23 2015-03-11 西安新通药物研究有限公司 Preparation method of high purity fenofibric acid
WO2015042411A1 (en) 2013-09-20 2015-03-26 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
WO2016110865A1 (en) 2015-01-06 2016-07-14 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and pain
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
DK3701971T3 (en) 2014-03-14 2022-10-24 Biomolecular Holdings Llc COMPOUNDS USEFUL IN THE PREPARATION OF HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL BOND
CN103951557B (en) * 2014-04-22 2016-06-08 徐州工业职业技术学院 A kind of method with inorganic base for catalyst preparing fenofibrate
WO2015184453A1 (en) 2014-05-30 2015-12-03 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (en) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compounds and compositions for the treatment of multiple sclerosis
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN104628554A (en) * 2015-02-09 2015-05-20 徐州工程学院 Fenofibric acid crystal form and preparation method thereof
CN106146444A (en) * 2015-04-03 2016-11-23 米文君 A kind of new compound and application thereof
CN105037180B (en) * 2015-04-19 2017-10-10 安徽省逸欣铭医药科技有限公司 Central analgesia noval chemical compound, the Preparation method and use of a kind of double action
US11357783B2 (en) * 2016-03-18 2022-06-14 Caregen Co., Ltd. Conjugate of finasteride with peptide
WO2017193562A1 (en) * 2016-05-10 2017-11-16 浙江海正药业股份有限公司 Water soluble rapamycin derivative
CN106316921B (en) * 2016-08-19 2019-03-29 河南东泰制药有限公司 A kind of preparation method of acemetacin
CN108948139B (en) * 2017-05-18 2021-10-26 首都医科大学 warfarin-4-O-acetyl-Arg-AA compounds, their synthesis, activity and use
CN108948140B (en) * 2017-05-18 2021-10-26 首都医科大学 warfarin-4-O-acetyl-Arg-AA eleven compounds, and synthesis, activity and application thereof
UY38072A (en) 2018-02-07 2019-10-01 Novartis Ag COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME
CN108299219A (en) * 2018-02-11 2018-07-20 中国农业大学 O- is acylated serine derivative and the preparation method and application thereof
HUE062848T2 (en) 2018-09-14 2023-12-28 Enlitisa Shanghai Pharmaceutical Co Ltd Conjugates of montelukast and peptides
EP4431115A4 (en) * 2022-03-28 2025-11-12 Chugai Pharmaceutical Co Ltd Pharmaceutical combination preparation with an oil component with polyoxyethylene structure
CN116041259A (en) * 2023-01-13 2023-05-02 武汉科技大学 Hydroxychloroquine derivative and preparation method thereof
CN116082439B (en) * 2023-03-13 2025-08-15 湖北南博生物工程有限公司 Aspirin derivative for treating coronary heart disease and preparation method and application thereof
CN117247327B (en) * 2023-10-13 2025-09-12 深圳市护家科技有限公司 Preparation method and application of bakuchiol derivatives and salts thereof
CN119954651B (en) * 2023-11-07 2025-11-28 深圳市护家科技有限公司 Anti-photoaging skincare products, antioxidant and anti-aging compounds and their uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5432183A (en) * 1991-05-31 1995-07-11 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5972379A (en) * 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
JPH1143467A (en) * 1997-05-14 1999-02-16 Ikeda Mohandou:Kk Fatty acid glyceride derivatives, glyceride derivatives, and methods for producing them
IT1294205B1 (en) * 1997-07-23 1999-03-24 Farmigea Spa PROCEDURE FOR THE SOLUBILIZATION IN WATER AND IN AQUEOUS VEHICLES OF PHARMACOLOGICALLY ACTIVE SUBSTANCES
JP2004517045A (en) * 2000-08-18 2004-06-10 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ Prodrugs of betulinic acid derivatives for treatment of cancer and HIV
US20020160988A1 (en) * 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
US7045543B2 (en) * 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
ATE396731T1 (en) * 2003-03-25 2008-06-15 Vertex Pharma THIAZOLES FOR USE AS INHIBITORS OF PROTEIN KINASES
KR20120116991A (en) * 2003-07-29 2012-10-23 시그너쳐 알 앤드 디 홀딩스, 엘엘씨 Amino acid prodrugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5432183A (en) * 1991-05-31 1995-07-11 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YANG C. ET AL.: "Chemical Stability, Enzymatic Hydrolysis, and Nasal Uptake of Amino Acid Ester Prodrugs of Acyclovir", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 90, no. 5, pages 617 - 624, XP008112431 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645792B2 (en) 2004-07-12 2010-01-12 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof

Also Published As

Publication number Publication date
KR20060073584A (en) 2006-06-28
AU2004289174A1 (en) 2005-05-26
NZ545570A (en) 2012-07-27
WO2005046575A2 (en) 2005-05-26
IL173382A0 (en) 2006-06-11
EP1660017A4 (en) 2011-03-09
CA2534342C (en) 2016-05-10
KR20130081319A (en) 2013-07-16
AU2004289174B2 (en) 2011-05-19
SG145693A1 (en) 2008-09-29
NZ601772A (en) 2012-10-26
KR20120116991A (en) 2012-10-23
JP2007510621A (en) 2007-04-26
CA2534342A1 (en) 2005-05-26
AU2004289174A2 (en) 2005-05-26
SG178721A1 (en) 2012-03-29
EP1660017A2 (en) 2006-05-31
ZA200600660B (en) 2007-04-25
JP2013035863A (en) 2013-02-21
CN101123878A (en) 2008-02-13
NZ601780A (en) 2012-10-26

Similar Documents

Publication Publication Date Title
WO2005046575A3 (en) Amino acid prodrugs
WO2007089745A3 (en) Novel compounds with high therapeutic index
WO2006037024A3 (en) Salts of decitabine
WO2005002515A3 (en) Delivery of therapeutic compounds to the brain and other tissues
TW200728307A (en) Novel spirochromanone derivatives
WO2004041203A3 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2006034154A3 (en) Salts of 5-azacytidine
WO2007135527A3 (en) Benzimidazolyl compounds
WO2009019534A3 (en) Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
IL193252A0 (en) N-hydroxyacrylamide compounds
WO2009071690A3 (en) 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
WO2005115470A3 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING β-CARBOLINE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER
WO2006029081A3 (en) Nucleoside-lipid conjugates, their method of preparation and uses thereof
UA97401C2 (en) Improved taste-masking extrudates
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2007123740A3 (en) Pharmaceutical compositions for promoting wound healing
MX2010004899A (en) Novel neurturin conjugates for pharmaceutical use.
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2007100668A3 (en) Antidepressant prodrugs
WO2007075923A3 (en) Treatment of synucleinopathies
WO2007110765A3 (en) Processes for the preparation of octreotide
WO2007103548A3 (en) Novel antibiotic compositions
WO2008022807A3 (en) Lipoxin a4 analogs for the treatment and prevention of intestinal fibrosis
WO2009016608A3 (en) Pharmaceutical compositions of fenofibrate
EP2457590A3 (en) Protein formulation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480028222.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006/00660

Country of ref document: ZA

Ref document number: 200600660

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2534342

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006522125

Country of ref document: JP

Ref document number: 11343557

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020067002214

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 942/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 545570

Country of ref document: NZ

REEP Request for entry into the european phase

Ref document number: 2004816791

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004816791

Country of ref document: EP

Ref document number: 2004289174

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004289174

Country of ref document: AU

Date of ref document: 20040729

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004289174

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004816791

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067002214

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 11343557

Country of ref document: US